We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.
AC Immune to Report Progress of Early-Stage Pipeline at AD/PD[TM] Congress
March 04, 2019



LAUSANNE, Switzerland, March 04, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will provide oral presentations addressing the progress of four of its early-stage product candidates and diagnostics at the 14thInternational Conference on Alzheimer’s and Parkinson’s Disease (AD/PD), taking place March 26th-31st in Lisbon.

The four oral presentations by AC Immune and its collaborators at AD/PD will focus on AC Immune’s partnered and wholly-owned product candidates and technology platform. These presentations will showcase the acceleration and diversification of its early-stage pipeline; specifically, its alpha-synuclein and Tau PET imaging agents as well as preclinical data on compounds targeting Tau aggregation and TDP-43 proteinopathies.

Prof. Andrea Pfeifer, Ph.D., CEO of AC Immune SA, commented: "We appreciate the opportunity to demonstrate the depth of the AC Immune pipeline to the scientific community at AD/PD. These programs highlight the importance of diagnosing and characterizing neurodegenerative diseases earlier. The findings show that our research capabilities have the potential to identify new ways to fight neurodegenerative diseases.  We believe the field is moving toward combination therapy and advancing potential therapeutics like these increases the opportunities to evaluate novel, multi-targeted product candidates.” 

Scientific updates at the International Conference on AD/PD conference, Lisbon, Portugal, March 26-31, 2019

Alpha-synuclein PET imaging agent

Identification and characterization of selective and high affinity small molecules for positron emission tomography (PET) imaging of pathological alpha-synuclein
Date: March 29, 2019 | 8.45 – 9.00 am WET
Location: Auditorium III+IV
Presenter: Oral presentation by F. Capotosti

Tau PET imaging agent

Determination of the optimal scanning time for the assessment of Tau deposition in Alzheimer’s disease using PI-2620 PET
Date: March 29, 2019 | 8.30 – 8.45 am WET
Location: Auditorium III+IV
Presenter: Oral presentation by A. Stephens

Compounds targeting Tau aggregation

Small molecules targeting Tau propagation demonstrate efficacy in an aggressive tauopathy mouse model
Date: March 31, 2019 | 11.00 – 11.15 am WET
Location: Auditorium II
Presenter: Oral presentation by S. Poli

Anti-TDP-43 antibodies

Discovery and development of diagnostics and therapeutics for TDP-43 proteinopathies
Date: March 31, 2019 | 11.45 am12.00 pm WET
Location: Auditorium II
Presenter: Oral presentation by T. Afroz

About AC Immune SA
AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for Neurodegenerative Diseases. The Company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune's two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Lilly, Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

For further information, please contact:

US Investors
Lisa Sher
AC Immune Investor Relations
Phone: +1 970 987 2654
E-mail: lisa.sher@acimmune.com
US Media
Katie Gallagher
LaVoieHealthScience
Phone: +1 617 792 3937
E-mail: kgallagher@lavoiehealthscience.com
 
European Investors & Media
Chris Maggos
LifeSci Advisors
Phone: +41 79 367 6254
E-mail: chris@lifesciadvisors.com
 

Forward looking statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

 

ac-immune-logo-rgb.png

 

AC Immune SA